Incannex Healthcare (IXHL) Proxy Filing summary

Executive summary

• The annual meeting is scheduled for December 11, 2024, in New York, with voting on key proposals including director election, auditor ratification, and significant stock issuances under new financing agreements.

• Stockholders of record as of October 24, 2024, are eligible to vote, with options to vote online, by phone, mail, or in person.

• The board recommends voting in favor of all proposals, which include measures to secure additional capital and maintain compliance with Nasdaq rules.

Voting matters and shareholder proposals

• Election of one director (Peter Widdows) for a three-year term expiring in 2027.

• Ratification of Grant Thornton Audit Pty Ltd as independent auditor for fiscal year ending June 30, 2025.

• Approval to issue 20% or more of outstanding common stock under an equity line of credit with Arena Global, including commitment fee shares and a warrant.

• Approval to issue 20% or more of outstanding common stock under a securities purchase agreement with purchasers, including conversion of debentures and exercise of warrants.

• Approval of any adjournment of the meeting to solicit additional proxies if needed.

Board of directors and corporate governance

• The board consists of five members divided into three classes, with staggered terms.

• Three directors are independent under Nasdaq rules; the board separates the roles of Chairperson and CEO.

• Audit and compensation committees are in place, with written charters available online.

• The board currently lacks diversity as defined by Nasdaq Rule 5605(f) but continues to evaluate candidates.